<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05003570</url>
  </required_header>
  <id_info>
    <org_study_id>ZDRF</org_study_id>
    <nct_id>NCT05003570</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of Remifentanil for Mechanically Ventilated Patients in ICU</brief_title>
  <official_title>Efficacy and Safety of Remifentanil for Mechanically Ventilated Patients in Intensive Care: Multicenter, Random, Double-blind, Parallel, Positive Control Clinical Trials</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Southeast University, China</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Southeast University, China</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Remifentanil has been approved by the FDA for continuation as an analgesic into the immediate&#xD;
      postoperative period in adult patients under the direct supervision of an anesthesia&#xD;
      practitioner in a postoperative anesthesia care unit or intensive care setting. However,&#xD;
      National Medical Products Administration(NMPA) did not approve this indication. Therefore,&#xD;
      the purpose of this study is to confirm the efficacy and safety of remifentanil in the&#xD;
      analgesic therapy of critical ill patients in China.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study was conducted in accordance with good clinical practice and with the guidelines set&#xD;
      out in the Declaration of Helsinki. After approval from local and national ethics committees,&#xD;
      patients from 18 centres in China were recruited. All patients were randomized, in a&#xD;
      double-blind manner, to receive either a remifentanil-propofol regimen or a fentanyl-propofol&#xD;
      regimen for analgesia and sedation in the ICU. The aim of the study was to achieve optimal&#xD;
      sedation and patient comfort by maintaining an optimal Critical Care Pain Observation Tool&#xD;
      (CPOT) score of 2, without clinically significant pain, until the start of the extubation&#xD;
      process or for 72 hours, whichever occurred first. CPOT scoring criteria: Facial&#xD;
      expressions(Relaxed, neutral=0; Tense=1; Grimacing=2); Body movements(Absence of movements or&#xD;
      normal position=0; Protection=1; Restlessness/Agitation=2); Muscle tension(Relaxed=0; Tense,&#xD;
      rigid=1; Very tense or rigid=2); Compliance with the ventilator or Vocalization(Tolerating&#xD;
      ventilator or movement/Talking in normal tone or no sound=0; Coughing but tolerating/Sighing,&#xD;
      moaning=1; Fighting ventilator/Crying out, sobbing=2).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">October 1, 2021</start_date>
  <completion_date type="Anticipated">August 30, 2022</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2022</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>analgesia success rate(the proportion of subjects with successful analgesia to the number of subjects in each group)</measure>
    <time_frame>From study drug administration to actual extubation , up to 72 hours</time_frame>
    <description>Analgesia success is defined as: 1. No salvage analgesics were used during the administration of the study drug; 2 During the administration of the study drug, the time for the analgesia score of subjects to reach the standard (CPOT score ≤ 2) was greater than 70%. CPOT scoring criteria: Facial expressions(Relaxed, neutral=0; Tense=1; Grimacing=2); Body movements(Absence of movements or normal position=0; Protection=1; Restlessness/Agitation=2); Muscle tension(Relaxed=0; Tense, rigid=1; Very tense or rigid=2); Compliance with the ventilator or Vocalization(Tolerating ventilator or movement/Talking in normal tone or no sound=0; Coughing but tolerating/Sighing, moaning=1; Fighting ventilator/Crying out, sobbing=2).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>During the study drug administration period, the subjects are in the proportion of optimal time(CPOT score≤2)</measure>
    <time_frame>From study drug administration to actual extubation , up to 72 hours</time_frame>
    <description>CPOT scoring criteria: Facial expressions(Relaxed, neutral=0; Tense=1; Grimacing=2); Body movements(Absence of movements or normal position=0; Protection=1; Restlessness/Agitation=2); Muscle tension(Relaxed=0; Tense, rigid=1; Very tense or rigid=2); Compliance with the ventilator or Vocalization(Tolerating ventilator or movement/Talking in normal tone or no sound=0; Coughing but tolerating/Sighing, moaning=1; Fighting ventilator/Crying out, sobbing=2).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The number of times the remedial sedative drug propofol was used</measure>
    <time_frame>From study drug administration to actual extubation , up to 72 hours</time_frame>
    <description>Use the total times of propofol</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The proportion of subjects using the salvage sedative drug propofol</measure>
    <time_frame>From study drug administration to actual extubation , up to 72 hours</time_frame>
    <description>The proportion of subjects who using the salvage sedative drug propofol to the total subjects.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The dosage of the remedial sedative drug propofol</measure>
    <time_frame>From study drug administration to actual extubation , up to 72 hours</time_frame>
    <description>Use the total dose of propofol</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Wearing time from mechanical ventilation</measure>
    <time_frame>From study drug administration to wearing from mechanical ventilation, up to 72 hours</time_frame>
    <description>Wearing time criteria: The primary disease is improved, and there is no new disease; no use of vasopressors or continuous application of sedative drugs; cough reflex during sputum suction; PEEP≤5cmH2O; PaO2/FiO2≥200mmHg; Minute ventilation&lt;15L/min; 2-minute spontaneous breathing test and passed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Extubation time</measure>
    <time_frame>From the start of the extubation process until actual extubation , up to 72 hours</time_frame>
    <description>The start of the extubation process until actual extubation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The success rate of wearing mechanical ventilator</measure>
    <time_frame>From study drug administration to actual extubation , up to 72 hours</time_frame>
    <description>The proportion of subjects who successfully wearing from mechanical ventilator to the total subjects.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of study drug use in ICU</measure>
    <time_frame>From study drug administration to the time discharge ICU , up to 72 hours</time_frame>
    <description>The time from the start of the study drug administration to the time discharge ICU.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The proportion of subjects discharging the ICU</measure>
    <time_frame>From study drug administration to the time discharge ICU, up to 24 weeks</time_frame>
    <description>The proportion of subjects who discharge ICU to the total subjects.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ICU mortality</measure>
    <time_frame>From study drug administration to the time discharge ICU, up to 24 weeks</time_frame>
    <description>The proportion of subjects who died during ICU admission to the total subjects.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hospital mortality</measure>
    <time_frame>From study drug administration to the time discharge hospital, up to 24 weeks</time_frame>
    <description>The proportion of subjects who died during hospital admission to the total subjects.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Length of ICU stay</measure>
    <time_frame>From administration to discharge ICU, up to 24 weeks</time_frame>
    <description>The number of days the subject stayed in the ICU</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Length of hospital stay</measure>
    <time_frame>From administration to discharge hospital, up to 24 weeks</time_frame>
    <description>The number of days the subject stayed in the hospital</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The incidence of study drug-related Lower blood pressure</measure>
    <time_frame>From study drug administration to actual extubation , up to 72 hours</time_frame>
    <description>Lower blood pressure: mean arterial pressure (MAP) drops more than 25% from the baseline level or requires additional vasopressors;</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The incidence of study drug-related slow heart rate</measure>
    <time_frame>From study drug administration to actual extubation , up to 72 hours</time_frame>
    <description>Slow heart rate: HR&lt;40bpm for less than 1 minute or HR&lt;60 bpm for more than 1 minute;</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The incidence of study drug-related respiratory depression</measure>
    <time_frame>From study drug administration to actual extubation , up to 72 hours</time_frame>
    <description>Respiratory depression: RR&lt;10 bpm or SpO2&lt;90%</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Analysis of the cost-effectiveness between remifentanil and fentanyl</measure>
    <time_frame>From study drug administration to actual extubation , up to 72 hours</time_frame>
    <description>cost-effectiveness</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">138</enrollment>
  <condition>Analgesia</condition>
  <arm_group>
    <arm_group_label>Remifentanil</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Remifentanil analgesia combined with propofol sedation. Treatment was started in patients with an CPOT score of 2 or greater after completion of baseline assessments. All patients received an initial infusion of blinded opioid (placebo bolus dose(6ml) + 6ug/kg per hour infusion at 6 ml/hour). Optimal analgesia (CPOT score ≤2) was then targeted by titrating the infusion in 1.5 ml/hour increments (placebo bolus dose + 1.5ug/kg per hour rate increase).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Fentanyl</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Fentanyl analgesia combined with propofol sedation. Treatment was started in patients with an CPOT score of 2 or greater after completion of baseline assessments. All patients received an initial infusion of blinded opioid (1ug/kg bolus(6ml) + 1ug/kg per hour infusion at 6ml/hour). Optimal analgesia (CPOT score ≤2) was then targeted by titrating the infusion in 1.5 ml/hour increments (1ug/kg bolus dose + 0.25ug/kg per hour rate increase).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Remifentanil</intervention_name>
    <description>Dosage forms and strengths: 3 mL Vial/1 mg lyophilized powder. Manufacturer: Yichang Humanwell Pharmaceutical Co.,Ltd</description>
    <arm_group_label>Remifentanil</arm_group_label>
    <other_name>Remifentanil Hydrochloride for Injection</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fentanyl</intervention_name>
    <description>Dosage forms and strengths: 50 mcg/mL Fentanyl base/10 mL ampules. Manufacturer: Yichang Humanwell Pharmaceutical Co.,Ltd</description>
    <arm_group_label>Fentanyl</arm_group_label>
    <other_name>Fentanyl Citrate Injection</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Intubated in the past 24 hours with invasive mechanical ventilation&#xD;
&#xD;
          -  Expected to continue mechanical ventilation for more than 48 hours&#xD;
&#xD;
          -  Informed consent/assent was obtained from all patients or their representatives&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients with a history of allergy to opioids, benzodiazepines, propofol, or&#xD;
             alcohol/drug abuse were excluded from the study&#xD;
&#xD;
          -  Patients who are known or suspected to be allergic to the study drug&#xD;
&#xD;
          -  Patients whose expected survival time is less than 48h&#xD;
&#xD;
          -  Patients receiving deep sedation (RASS≥-4)&#xD;
&#xD;
          -  Patients using neuromuscular blocking agent&#xD;
&#xD;
          -  Patients who cannot be assessed by RASS&#xD;
&#xD;
          -  Patients with myasthenia gravis&#xD;
&#xD;
          -  patients with bronchial asthma&#xD;
&#xD;
          -  patients with abdominal compartment syndrome&#xD;
&#xD;
          -  Patients who need surgery or tracheotomy during the study drug treatment period&#xD;
&#xD;
          -  Women during pregnancy and lactation&#xD;
&#xD;
          -  Patients who have used short-acting non-steroidal anti-inflammatory drugs within 6&#xD;
             hours&#xD;
&#xD;
          -  Patients who have used long-acting non-steroidal anti-inflammatory drugs within 12&#xD;
             hours&#xD;
&#xD;
          -  Patients with a history of chronic pain for more than 3 months or who are receiving&#xD;
             regular analgesia for more than 3 months&#xD;
&#xD;
          -  Patients who have used monoamine oxidase inhibitors within two weeks&#xD;
&#xD;
          -  Patients who participate in any clinical trials as subjects within 1 month&#xD;
&#xD;
          -  Patients with a history of drug abuse, drug abuse, alcohol abuse* and long-term use of&#xD;
             psychotropic drugs within 2 years Alcoholism: Drinking more than 14 times/week (1&#xD;
             time=150ml wine or 360ml beer or 45ml spirits)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yang Yi, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Department of Critical Care Medicine, Zhongda Hospital, School of Medicine, Southeast University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Yang Yi, MD</last_name>
    <phone>+86-25-83262552</phone>
    <email>yiyiyang2004@163.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Liu Ling, MD</last_name>
    <phone>13851435472</phone>
    <email>liulingdoctor@126.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Anhui Provincial People's Hospital</name>
      <address>
        <city>Hefei</city>
        <state>Anhui</state>
        <zip>230000</zip>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Pan Aijun, MD</last_name>
      <phone>+8613866668786</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Beijing Tiantan Hospital, Capital Medical University</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100000</zip>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Zhou Jianxin, MD</last_name>
      <phone>+8613801183875</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>The First Affiliated Hospital of Chongqing Medical University</name>
      <address>
        <city>Chongqing</city>
        <state>Chongqing</state>
        <zip>404100</zip>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Zhou Fachun, MD</last_name>
      <phone>+8618502388799</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Qingyuan People's Hospital</name>
      <address>
        <city>Qingyuan</city>
        <state>Guangdong</state>
        <zip>511500</zip>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Yang Jingwen, MD</last_name>
      <phone>+8613542498765</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Affiliated Hospital of Guizhou Medical University</name>
      <address>
        <city>Guiyang</city>
        <state>Guizhou</state>
        <zip>550000</zip>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Shen Feng, MD</last_name>
      <phone>+8613511999117</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Affiliated Hospital of Zunyi Medical University</name>
      <address>
        <city>Zunyi</city>
        <state>Guizhou</state>
        <zip>563000</zip>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Chen Tao, MD</last_name>
      <phone>+8615329112288</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Fourth Hospital of Hebei Medical University</name>
      <address>
        <city>Shijiazhuang</city>
        <state>Hebei</state>
        <zip>050000</zip>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Hu Zhenjie, MD</last_name>
      <phone>+8613933856908</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>First Affiliated Hospital of Zhengzhou University</name>
      <address>
        <city>Zhengzhou</city>
        <state>Henan</state>
        <zip>450000</zip>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Sun Tongwen, MD</last_name>
      <phone>+8613838516916</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Henan Provincial People's Hospital</name>
      <address>
        <city>Zhengzhou</city>
        <state>Henan</state>
        <zip>450000</zip>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Qin Bingyu, MD</last_name>
      <phone>+8613633810677</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Enshi Tujia and Miao Autonomous Prefecture Central Hospital</name>
      <address>
        <city>Enshi</city>
        <state>Hubei</state>
        <zip>445000</zip>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Li Dezhong, MD</last_name>
      <phone>+8615342885588</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Zhongnan Hospital of Wuhan University</name>
      <address>
        <city>Wuhan</city>
        <state>Hubei</state>
        <zip>430000</zip>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Peng Zhiyong, MD</last_name>
      <phone>+8618672396028</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Third Xiangya Hospital of Central South University</name>
      <address>
        <city>Changsha</city>
        <state>Hunan</state>
        <zip>410000</zip>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Yang Mingshi, MD</last_name>
      <phone>+8613973139006</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Xiangya Hospital of Central South University</name>
      <address>
        <city>Changsha</city>
        <state>Hunan</state>
        <zip>410000</zip>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Zhang Lina, MD</last_name>
      <phone>+8615874875763</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Nanjing Zhong-Da Hospital, Southeast University</name>
      <address>
        <city>Nanjing</city>
        <state>Jiangsu</state>
        <zip>210009</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Northern Jiangsu People's Hospital</name>
      <address>
        <city>Yangzhou</city>
        <state>Jiangsu</state>
        <zip>225000</zip>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Zheng Rui qiang, MD</last_name>
      <phone>+8613952721411</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>The First Affiliated Hospital of Xi'an Jiaotong University</name>
      <address>
        <city>Xi'an</city>
        <state>Shanxi</state>
        <zip>710000</zip>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Shi Qindong, MD</last_name>
      <phone>+8618991232391</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Tianjin First Central Hospital</name>
      <address>
        <city>Tianjin</city>
        <state>Tianjin</state>
        <zip>30000</zip>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Wang Yongqiang, MD</last_name>
      <phone>+8613302048899</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Zhejiang Provincial People's Hospital</name>
      <address>
        <city>Hangzhou</city>
        <state>Zhejiang</state>
        <zip>310000</zip>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Sun Renhua, MD</last_name>
      <phone>+8613505710366</phone>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>June 30, 2021</study_first_submitted>
  <study_first_submitted_qc>August 3, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 12, 2021</study_first_posted>
  <last_update_submitted>September 13, 2021</last_update_submitted>
  <last_update_submitted_qc>September 13, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 16, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Southeast University, China</investigator_affiliation>
    <investigator_full_name>Ling Liu</investigator_full_name>
    <investigator_title>professor</investigator_title>
  </responsible_party>
  <keyword>analgesia</keyword>
  <keyword>analgesia based sedation</keyword>
  <keyword>critical care</keyword>
  <keyword>fentanyl</keyword>
  <keyword>propofol</keyword>
  <keyword>remifentanil</keyword>
  <keyword>sedation</keyword>
  <keyword>mechanical ventilation</keyword>
  <keyword>efficacy</keyword>
  <keyword>safety</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fentanyl</mesh_term>
    <mesh_term>Remifentanil</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

